1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Sernova Seeks Cash And A Partner To Move Type 1 Diabetes Cell Therapy Forward

 
• By Jessica Merrill

The company’s CEO Cynthia Pussinen joined the company last year and talked to Scrip about her plans to advance a cell therapy for type 1 diabetes.

insulin injection
Sernova is working on a drug/device that would eliminate insulin injections for type 1 diabetes • Source: Shutterstock

Sernova Corp is working to develop a functional cure for type 1 diabetes that could free patients from a lifetime of insulin injections, but despite some early encouraging clinical data and a potentially large commercial opportunity, the company is running low on cash and is competing against a well-capitalized rival.

Key Takeaways
  • Sernova is looking to complete a round of financing and would consider a potential partnership with a larger pharmaceutical player, CEO Cynthia Pussinen said.

The small Canadian biotech needs to complete a round of financing and would consider a potential partnership with a larger...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By Kevin Grogan

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

BioNTech/BMS Bispecific Shows Early Promise In Small Cell Lung Cancer

 
• By Andrew McConaghie

An updated abstract from the World Conference on Lung Cancer has given analysts confidence in BioNTech’s VEGF-A/PD-L1 bispecific challenger

China-Originated Assets Lead Global GLP-1 Deals

 
• By Xu Hu

The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.